Login to Your Account

BACE1cally kaput? Merck stops Alzheimer's study for lack of efficacy

By Michael Fitzhugh
Staff Writer

Wednesday, February 15, 2017

Merck & Co. Inc. is calling a halt to a high-profile phase II/III study of verubecestat after data monitors found "virtually no chance of finding a positive clinical effect" for patients with mild to moderate Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription